Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Minimal residual disease assessment in chronic lymphocytic leukaemia.

Best practice & research. Clinical haematology - 1 Sept 2007

Sayala Hazem A, Rawstron Andy C, Hillmen Peter

Abstract excerpt

The concept of minimal residual disease (MRD) eradication in chronic lymphocytic leukaemia (CLL) is a relatively new one, as conventional therapy with alkylating agents is relatively ineffective and responding patients almost always have a significant tumour burden remaining at the end of treatment. However, a variety of novel therapies is now yielding higher response rates, and responses of better quality are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antigens, CD19
Share to CD5 Antigens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Neoplasm, Residual

Share to Stem Cell Transplantation

Share to Vidarabine

Source

Identifiers

PMID: 17707836
DOI: 10.1016/j.beha.2007.03.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Minimal residual disease assessment in chronic lymphocytic leukaemia.PMID 17707836Read ↗

A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia?Semantic proximity Read ↗

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.Semantic proximity Read ↗

Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR.Semantic proximity Read ↗

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment.Semantic proximity Read ↗

Chronic Lymphocytic Leukemia: Current Concepts.Semantic proximity Read ↗

Chronic lymphocytic leukaemia.Semantic proximity Read ↗

Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived.Semantic proximity Read ↗

Update on therapy of chronic lymphocytic leukemia.Semantic proximity Read ↗

Detection of minimal residual disease in leukemias: a critical approach.Semantic proximity Read ↗

Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future PerspectivesSemantic proximity Read ↗

B Lymphoblastic Leukemia Minimal Residual Disease Assessment by Flow Cytometric AnalysisSemantic proximity Read ↗

Advances in the assessment of minimal residual disease in mantle cell lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.